| Business Summary | | Amarin
Corporation
plc
is
an
emerging
specialty
pharmaceutical
company
that
markets
and
sells
United
States
brand-name
prescription
and
over-the-counter
drugs
to
high
prescribing
primary
care
and
select
specialty
physicians
through
sales
force
activities
and
via
the
Internet.
The
Company
focuses
on
conditions
such
as
migraine,
anti-diarrheals,
anti-obesity
and
cough,
cold
and
respiratory.
The
Company's
key
products
include
the
anti-diarrheals
product
Motofen,
the
migraine
and
tension
headache
products
Phrenilin
and
Phrenilin
Forte,
the
anti-obesity
product
Bontril
and
the
cold
and
allergy
product
Nolamine.
Additional
products
in
the
range
include
Capital
with
Codeine,
Salflex
and
Hydrocet
for
pain
management,
Nolahist,
Exgest,
Sinulin
and
Propagest
for
cough,
cold
and
allergy
symptoms. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Amarin
Corporation
plc
is
a
pharmaceutical
company
that
markets
and
sells
United
States
brand-name
prescription
and
over-the-counter
drugs
to
high
prescribing
primary
care
and
select
specialty
physicians.
For
the
six
months
ended
6/01,
revenues
totalled
$24.3
million,
up
from
$7.9
million.
Net
income
before
U.S.
GAAP
totalled
$8
million,
vs.
a
loss
of
$86
thousand.
Results
reflect
increased
product
sales,
along
with
investment
gains
instead
of
losses. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Thomas Lynch, 43 | Chairman | Richard Stewart, 41 | CEO,
Director | Michael Coffee | Pres,
COO | Nigel Bell, 30 | CFO | Martyn Pitman, 46 | VP,
Corp. Affairs and Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|